<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Overweight and <z:hpo ids='HP_0001513'>obesity</z:hpo> are now recognized as leading causes of diseases such as type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo>, and ultimately, <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Despite the serious consequences, roughly two thirds of Americans are presently classified as overweight, and about one third are classified as <z:mp ids='MP_0001261'>obese</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0001824'>Weight loss</z:hpo> via lifestyle modification and pharmacotherapy can promote improvement in many of these <z:hpo ids='HP_0001513'>obesity</z:hpo>-related conditions </plain></SENT>
<SENT sid="3" pm="."><plain>This review addresses recent advances in pharmacotherapy for the management of <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:hpo ids='HP_0001513'>obesity</z:hpo>-related co-morbidities, with a focus on the management of <z:hpo ids='HP_0001513'>obesity</z:hpo> specifically in individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Emphasis is also placed on a proposed paradigm shift from the <z:chebi fb="105" ids="17234">glucose</z:chebi>-centric to the weight-centric management of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>